Bruce A. Littlefield
- Oncology top 2%
- Cancer Treatment and Pharmacology 22
- Biotechnology top 2%
- Marine Sponges and Natural Products 6
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms 8
- Cell Biology top 5%
- Microtubule and mitosis dynamics 14
- Toxicology top 2%
-
- Multiple Myeloma Research and Treatments 7
- Blood Coagulation and Thrombosis Mechanisms 6
-
- Microbial Natural Products and Biosynthesis 6
-
- Cancer therapeutics and mechanisms 6
- Co-authors
- Mary Ann JordanLeslie WilsonMurray J. TowleTatiana OkounevaMelvin J. YuOlga AzarenkoYoshito KishiBryan M. Lewis
- Cited by
- OncologyBiotechnologyCancer Research
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Oncology (1 paper)Blood (1 paper)
- Partner nations
- United StatesJapanSpain
In The Last Decade
Bruce A. Littlefield
71 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 115
- Oncology 1.4k
- Biotechnology 273
- Cancer Research 419
- Cell Biology 426
- Toxicology 81
Countries citing papers authored by Bruce A. Littlefield
This map shows the geographic impact of Bruce A. Littlefield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce A. Littlefield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce A. Littlefield more than expected).
Fields of papers citing papers by Bruce A. Littlefield
This network shows the impact of papers produced by Bruce A. Littlefield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce A. Littlefield. The network helps show where Bruce A. Littlefield may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bruce A. Littlefield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2022 | 12 | |
| 3 | 2021 | 8 | |
| 4 | 2018 | 56 | |
| 5 | 2017 | 20 | |
| 6 | Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin- Insensitive Tumor Cells | 2015 | 1 |
| 7 | Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. | 2012 | 38 |
| 8 | 2011 | 75 | |
| 9 | In vitro and in vivo anticancer activity of (+)-spongistatin 1. | 2011 | 17 |
| 10 | 2011 | 12 | |
| 11 | 2011 | 16 | |
| 12 | 2010 | 111 | |
| 13 | 2009 | 85 | |
| 14 | Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts | 2009 | 3 |
| 15 | Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro | 2007 | 40 |
| 16 | Synthetic analogs of the marine natural product hemiasterlin: Optimization and discovery of E7974, a novel and potent antitumor agent | 2005 | 3 |
| 17 | A 96-well plate cell-based assay to quantify undesired cytotoxic effects against quiescent non-dividing cells | 2004 | 3 |
| 18 | E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block | 2004 | 2 |
| 19 | 2000 | 41 | |
| 20 | 1993 | 22 |
About Bruce A. Littlefield
Bruce A. Littlefield is a scholar working on Hematology, Oncology and Cell Biology, having authored 72 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (22 papers), Microtubule and mitosis dynamics (14 papers), Protease and Inhibitor Mechanisms (8 papers), Multiple Myeloma Research and Treatments (7 papers), Microbial Natural Products and Biosynthesis (6 papers), Cancer therapeutics and mechanisms (6 papers), Marine Sponges and Natural Products (6 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). The work is most often cited by research in Oncology (1.4k citations), Biotechnology (273 citations) and Cancer Research (419 citations). Bruce A. Littlefield has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Mary Ann Jordan, Leslie Wilson, Murray J. Towle, Tatiana Okouneva, Melvin J. Yu, Olga Azarenko, Yoshito Kishi, Bryan M. Lewis, Herbert P. Miller and Galina Kuznetsov. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.